Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Paracchi

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
The Journal of Clinical Endocrinology and Metabolism|June 1, 1979
Thyrotropin secretion in patients with central hypothyroidism: evidence for reduced biological activity of immunoreactive thyrotropinG Faglia, L Bitensky, A Pinchera, et al.
Acta Endocrinologica|February 1, 1976
Some aspects of hypothalamic-pituitary function in patients with anorexia nervosaP Travaglini, P Beck-Peccoz, C Ferrari, et al.
The Journal of Clinical Endocrinology and Metabolism|October 1, 1986
Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patientsC Ferrari, C Barbieri, R Caldara, et al.
The Journal of Clinical Endocrinology and Metabolism|June 1, 1989
Cabergoline: long-acting oral treatment of hyperprolactinemic disordersC Ferrari, A Mattei, G B Melis, et al.
Minerva Medica|June 16, 1979
[Hyperprolactinemia and gonadal deficit]G Faglia, P Travaglini, M Rondena, et al.
Acta Endocrinologica|September 1, 1983
Thyroid autoimmunity in hyperprolactinaemic disordersC Ferrari, M Boghen, A Paracchi, et al.
Gynecologic and Obstetric Investigation|January 1, 1983
Prolactin response to the dopamine antagonists sulpiride and domperidone. Further evidence for pituitary dopamine deficiency in hyperprolactinemic disorders of different etiologyC Ferrari, C Scarduelli, P Rampini, et al.
The Journal of Clinical Endocrinology and Metabolism|January 1, 1988
Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patientsA M Mattei, C Ferrari, P Baroldi, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
The Journal of Clinical Endocrinology and Metabolism|June 1, 1979
Thyrotropin secretion in patients with central hypothyroidism: evidence for reduced biological activity of immunoreactive thyrotropinG Faglia, L Bitensky, A Pinchera, et al.
Acta Endocrinologica|February 1, 1976
Some aspects of hypothalamic-pituitary function in patients with anorexia nervosaP Travaglini, P Beck-Peccoz, C Ferrari, et al.
The Journal of Clinical Endocrinology and Metabolism|October 1, 1986
Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patientsC Ferrari, C Barbieri, R Caldara, et al.
The Journal of Clinical Endocrinology and Metabolism|June 1, 1989
Cabergoline: long-acting oral treatment of hyperprolactinemic disordersC Ferrari, A Mattei, G B Melis, et al.
Minerva Medica|June 16, 1979
[Hyperprolactinemia and gonadal deficit]G Faglia, P Travaglini, M Rondena, et al.
Acta Endocrinologica|September 1, 1983
Thyroid autoimmunity in hyperprolactinaemic disordersC Ferrari, M Boghen, A Paracchi, et al.
Gynecologic and Obstetric Investigation|January 1, 1983
Prolactin response to the dopamine antagonists sulpiride and domperidone. Further evidence for pituitary dopamine deficiency in hyperprolactinemic disorders of different etiologyC Ferrari, C Scarduelli, P Rampini, et al.
The Journal of Clinical Endocrinology and Metabolism|January 1, 1988
Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patientsA M Mattei, C Ferrari, P Baroldi, et al.
Pageof 4